呼吸器官藥品市場觀察分析：2008年 是由出版商Visiongain在2008年02月所出版的。
這份英文市場調查報告書包含135 pages 價格從美金2331起跳。
Abstract
This brand new report examines the forthcoming prospects for respiratory drugs
over the next 5 year. With in-depth sales forecasts for leading pharmaceutical
products, the report has been produced to inform you of future developments
and strategies. The respiratory market generated revenues of $30503m in 2006,
but what will it be in 2013,? Which year will see it reach its peak? This
report tells you.
The respiratory market contained ten blockbuster drugs in 2006, with the top
three being; Advair/Seretide, Singulair and Zyrtec. Visiongain predicts that
there will be room for more blockbusters as the current products lose patent
protection. This detailed report also highlights pipeline developments and
important contemporary issues, especially commercial drivers and restraints.
The prevalence of respiratory diseases such as asthma, in the leading
pharmaceutical markets, has increased significantly over the past few decades.
Although there is some evidence to suggest that the rate of increase is
slowing, we believe that the prevalence will continue to increase and be a key
driver of this market throughout the forecast period of the report.
Sources include primary interviews and analysis unavailable elsewhere,
in-house industry databases, commercial news, published reports, economic
research and consultation with experts. Visiongain applies financial
forecasting, qualitative analyses and the assessment of unmet needs to provide
a comprehensive market report with detailed analysis and informed opinion.
In particular, The Respiratory Market concentrates on the following essential
aspects of the market:
- Discussion of the current pharmaceutical market
- Forecast of the worldwide pharmaceutical market from 2008-2013
- Drivers and restraints facing the respiratory market
- Opportunities and threats facing the respiratory market
- Growth of the respiratory drugs market between 2008-2013
- Commercial prospects for the market-leading drugs, with sales forecasts
from 2008-2013
- Individual forecasts of the leading drug classes from 2008-2013
- The potential of generics manufacturers to penetrate this market
- Pipeline developments with blockbuster potential
- Currently marketed drugs with blockbuster potential
- Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for respiratory drugs
from 2008-2013
- To discover predicted revenues, growth rates and other key metrics for
leading pharmaceutical treatments from 2008-2013
- To determine key activities of leading companies
- To discover "hot" pipeline developments and up-and-coming products
- To determine the forces that influence the market for respiratory products:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats (SWOT analysis)
- To find out where the market is heading - both technologically and
commercially
Do you know what the market values of these major therapeutic areas of the
respiratory market are?
The report provides in-depth market analysis upon these areas, and extensively
identifies both prescription and OTC respiratory drugs by product type. The
study also assess' the challenges faced by respiratory companies, and what
exciting market opportunities exist in this up- and-coming therapeutic area.
Why You Must Buy This Report?
This report features over 40 figures & graphs, 15 tables and charts, news,
insights, the latest developments and an in depth survey of the respiratory
market with up-to-date analysis. This report is a vital addition to gaining an
understanding of this highly profitable market sector and will give your
company ' the edge' on your competitors. You can not afford to be without this
latest report from visiongain.
Table of Contents
Chapter 1 Executive Summary
- 1.1 The Respiratory Treatment Market Has High Potential
- 1.2 Combination Class Leads the Market
- 1.3 GSK Dominates the Market
- 1.4 Aims, Scope and Format of the Report
Chapter 2 Introduction
- 2.1 Respiratory Diseases Overview
- 2.2 What is Asthma?
- 2.2.1 Causes of Asthma
- 2.2.2 Asthma Triggers
- 2.2.3 Asthma Rates Have Exploded in Recent Years
- 2.2.4 The Economic Cost of Asthma Has Increased
- 2.2.5 Asthma: Drug Treatments
- 2.2.6 Inhaler is Main Delivery Method for Asthma
- 2.3 Chronic Obstructive Pulmonary Disease (COPD)
- 2.3.1 Chronic Bronchitis
- 2.3.2 Emphysema
- 2.3.3 Symptoms of COPD
- 2.3.4 Management of COPD
- 2.3.5 Frequent Exacerbations in Patients with COPD
- 2.4 Upper Respiratory Infections (URI)
- 2.4.1 Common Cold
- 2.4.2 Influenza
- 2.4.3 Sinusitis
- 2.4.4 Pharyngitis / Tonsillitis
- 2.4.5 Allergic Rhinitis
- 2.5 Major Drug Classes in Treating Respiratory Diseases
- 2.5.1 Combination
- 2.5.2 Leukotriene Inhibitors
- 2.5.3 Corticosteroids
- 2.5.4 Beta-2 (Adrenoreceptor) Agonists
- 2.5.5 Antihistamines
- 2.5.6 Monoclonal Antibodies
- 2.5.7 Summary of Major Products in the Respiratory Market
Chapter 3 The Global Respiratory Disease Drug Market
- 3.1 The Global Respiratory Disease Drug Market Will Grow During 2008-2013
- 3.2 GSK Currently Leads the Respiratory Market
- 3.3 Combination Drugs to Continue Their Domination of the Respiratory
Disease Market, 2006 Onwards
- 3.4 Other Classes of Respiratory Drugs Will Display High Revenues during
2006-2013
- 3.5 Antihistamines - Declining Revenues due to Heightened Competition
- 3.6 B2-Stimulants - Will This Class Be Superseded by the Combination Drugs?
- 3.7 Corticosteroids - Carving a Secure Niche in a Highly Competitive Market
- 3.8 Leukotriene Inhibitors Will Maintain a Respected Position in the
Respiratory Market
- 3.9 Competition in the Respiratory Disease Drug Market to Become
Increasingly Intense
Chapter 4 The World Market for Combination Drugs, 2008-2013
- 4.1 Combination Drugs - Strong Growth Leads to Continuing Predominance in
the Market
- 4.1.1 Will the Combination Drugs Hold Their Dominance Towards the End of
the Forecast Period?
- 4.2 GSK' s Advair/Seretide Currently Leads the Respiratory Market
- 4.2.1 Advair/Seretide Benefits From High Prescription Rates in the US
Market
- 4.2.2 Advair/Seretide Benefits from Further Clinical Studies
- 4.3 Symbicort - High Revenues Followed by Decline
- 4.3.1 New Formulation and Delivery Method Looks Promising
- 4.3.2 New Dosing Regime May Offer Symbicort Significant Market Advantages
- 4.3.3 Is AstraZeneca Pushing Towards a New Model of Asthma Treatment?
- 4.4 Combivent Will Reach Blockbuster Status
Chapter 5 The World Market for Antihistamines, 2008-2013
- 5.1 Increased Competition Will Lower Revenues Among the Antihistamines
- 5.2 Will Pfizer' s Zyrtec Still Dominate the Antihistamine Market After
Patent Expiration?
- 5.2.1 Zyrtec Faces Generic Competition
- 5.3 Allegra/Telfast Will Decline in Revenue
- 5.3.1 Allegra/Telfast has Some Positive and Negative Clinical Data
- 5.4 Clarinex/Aerius Will Show Some Positive Growth but then Gradually
Decline
Chapter 6 The World Market for Corticosteroids, 2008-2013
- 6.1 Corticosteroids Will Retain Their Niche Despite a Marked Decline in
Sales
- 6.2 Pulmicort from AstraZeneca is the Market Leader - But will it Last?
- 6.2.1 Why Will Pulmicort' s Revenue Drop?
- 6.3 Flovent/Flixotide Will Gradually Decline in Sales
- 6.4 Nasonex Will Become the Leading Product in this Market
- 6.4.1 Nasonex Benefits From the Patent Expiry of Other Leading Products
in this Class
- 6.5 Summary - Corticosteroids
Chapter 7 The World Market for Leukotriene Inhibitors, 2008-2013
- 7.1 Singulair Dominates the Leukotriene Inhibitor Class
- 7.2 Summary - Leukotriene Inhibitors
Chapter 8 The World Market for Monoclonal Antibodies, 2008-2013
- 8.1 The Monoclonal Antibodies Will Face Decreased Growth
- 8.2 MedImmune' s Synagis Leads This Market
- 8.2.1 Synagis Benefits from Further Clinical Studies
- 8.3 Xolair Shows Steady Growth - Will it Become the New Market Leader?
Chapter 9 The World Market for B2-Stimulants, 2008-2013
- 9.1 B2-Stimulants Will Lose Prominence in the Respiratory Market
- 9.2 Xopenex Will Dominate the B2-Stimulants Class Despite Mixed Growth
- 9.3 Serevent Loses Revenue Despite Patent Protection
- 9.4 Recent Study Confirms Increased Risk With Beta-2 Agonist Usage
- 9.5 Summary - Beta-2 Agonists
Chapter 10 Analysis of Factors That Influence the Respiratory Market
- 10.1 SWOT Analysis of the Respiratory Market
- 10.2 An Expanding Patient Population Constitutes the Principal Driver in
the Respiratory Market
- 10.2.1 The Respiratory Disease Market Has High Potential and
Opportunities
- 10.2.2 Growth in this Market Is Driven by Epidemiological Factors
- 10.2.3 Lifecycle Management Strategies Will Become More Prominent to
Protect Soon-to-be Off-patent Drugs
- 10.2.4 Brand Awareness in the Respiratory Disease Market
- 10.3 The Principal Restraints in the Respiratory Market
- 10.3.1 To What Extent is the Respiratory Market Threatened by Generic
Substitutes?
- 10.3.2 Warnings Act as Restraints to Market Growth
- 10.3.3 Comparative Studies - A Two Edged Sword
- 10.4 What has Caused a Broadening of the Focus in Respiratory Drug
Development?
- 10.5 Respiratory Disease - A Unique Market Based on Management Rather than
Cure
- 10.6 Increasing Investment in the ' Cinderella Sector'
- 10.7 The Future for Respiratory Disease Research and Development and the
Increasing Focus on COPD
- 10.8 The Importance of Education in the Future of the Respiratory Disease
Market
- 10.9 Is the Early Treatment of Asthma the Way Ahead?
Chapter 11 Respiratory Pipeline Products
- 11.1 Summary of All Respiratory Pipeline Products
- 11.2 The Respiratory Pipeline is Large
- 11.3 NVA237 and QVA149 for COPD
- 11.4 New Companies Seek Entrance Into a Potentially Lucrative Market
- 11.5 The Potential of the Respiratory Market Has Encouraged R&D
- 11.6 Innovation Rules For Early Stage Pipeline Drugs
- 11.7 Respiratory Pipeline Shows Short- and Long-Term Potential
Chapter 12 Conclusion
- 12.1 The Respiratory Market Constitutes a High Revenue Market with
Continuing Growth Potential
- 12.2 Combination Class Will Dominate During the Forecast Period
- 12.3 Unmet Needs in the Market
- 12.4 Future Opportunities in the Respiratory Market
List of Tables
- Table 1.1 Blockbuster Drugs in the World Respiratory Market
- Table 2.1 Summary of the Major Products in the Respiratory Market and
Revenues ($m), 2006
- Table 3.1 Blockbuster Drugs in the World Respiratory Disease Market, 2006
- Table 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by Class,
2008-2013
- Table 3.3 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%)
for Respiratory Drugs by Class, 2006 & 2013
- Table 4.1 World Revenues ($m) for Combination Drugs, 2008-2013
- Table 4.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR
(%) for Combination Drugs, 2006 & 2013
- Table 5.1 World Revenues ($m) for Antihistamines, 2008-2013
- Table 5.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR
(%) for Antihistamines, 2006 & 2013
- Table 6.1 World Revenues ($m) for Corticosteroids, 2008-2013
- Table 6.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR
(%) for Corticosteroids, 2006 & 2013
- Table 7.1 World Revenues ($m) and Growth Rate (%) for Singulair, 2008-2013
- Table 8.1 World Revenues ($m) for Monoclonal Antibodies, 2008-2013
- Table 8.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR
(%) for Monoclonal Antibodies, 2006 & 2013
- Table 9.1 World Revenues ($m) for B2-Stimulants, 2008-2013
- Table 9.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR
(%) for B2-Stimulants, 2006 & 2013
- Table 10.1 A SWOT Chart for the Respiratory Market, 2008-2013
- Table 11.1 Pipeline Drugs for Respiratory Diseases, 2008
List of Figures
- Figure 1.1 Market Share (%) for the Respiratory Market by Company, 2006
- Figure 3.1 World Revenues ($m) for the Leading Respiratory Drugs, by
Class, 2008-2013
- Figure 3.2 World Revenues ($m) for the Leading Respiratory Drugs, by
Class, 2008-2013
- Figure 3.3 World Market Share (%) for Respiratory Drugs by Class, 2006
- Figure 3.4 World Market Share (%) for Respiratory Drugs by Class, 2013
- Figure 4.1 Total World Revenues ($m) for Combination Drugs, 2008-2013
- Figure 4.2 World Revenues ($m) for the Combination Drugs by Leading
Product, 2008-2013
- Figure 4.3 World Market Share (%) for Combination Drugs by Leading
Product, 2006
- Figure 4.4 World Market Share (%) for Combination Drugs by Leading
Product, 2013
- Figure 4.5 World Advair/Seretide Revenues ($m), 2008-2013
- Figure 4.6 World Symbicort Revenues ($m), 2008-2013
- Figure 4.7 World Combivent Revenues ($m), 2008-2013
- Figure 5.1 Total World Revenues ($m) for Antihistamines, 2008-2013
- Figure 5.2 World Revenues ($m) for the Antihistamines by Leading Product,
2008-2013
- Figure 5.3 World Market Share (%) for Antihistamines by Product, 2006
- Figure 5.4 World Market Share (%) for Antihistamines by Product, 2013
- Figure 5.5 World Zyrtec Revenues ($m), 2008-2013
- Figure 5.6 World Allegra/Telfast Revenues ($m), 2008-2013
- Figure 5.7 World Clarinex/Aerius Revenues ($m), 2008-2013
- Figure 6.1 Total World Revenues ($m) for Corticosteroids, 2008-2013
- Figure 6.2 World Revenues ($m) for the Corticosteroids by Leading Product,
2008-2013
- Figure 6.3 World Market Share (%) for Corticosteroids, 2006
- Figure 6.4 World Market Share (%) for Corticosteroids, 2013
- Figure 6.5 World Pulmicort Revenues ($m), 2008-2013
- Figure 6.6 Flovent/Flixotide Revenues ($m), 2008-2013
- Figure 6.7 World Nasonex Revenues ($m), 2008-2013
- Figure 7.1 World Revenues ($m) for Singulair, 2008-2013
- Figure 8.1 Total World Revenues ($m) for Monoclonal Antibodies, 2008-2013
- Figure 8.2 World Revenues ($m) for the Monoclonal Antibodies by Leading
Product, 2008-2013
- Figure 8.3 World Market Share (%) for Monoclonal Antibodies, 2006
- Figure 8.4 World Market Share (%) for Monoclonal Antibodies, 2013
- Figure 8.5 World Synagis Revenues ($m), 2008-2013
- Figure 8.6 World Xolair Revenues ($m), 2008-2013
- Figure 9.1 Total World Revenues ($m) for B2-Stimulants, 2008-2013
- Figure 9.2 World Revenues ($m) for the B2-Stimulants by Leading Product,
2008-2013
- Figure 9.3 World Market Share (%) for B2-Stimulants, 2006
- Figure 9.4 World Market Share (%) for B2-Stimulants, 2013
- Figure 9.5 World Xopenex Revenues ($m), 2008-2013
- Figure 9.6 World Serevent Revenues ($m), 2008-2013
List of Companies Mentioned
- 3M
- Abbott
- Actelion
- Almirall
- ALZA
- AstraZeneca
- Barrier Therapeutics
- Boehringer Ingelheim
- Chiesi
- Chugai
- Collegium
- Eli Lilly
- Evolutec
- FAES
- Forest
- Genentech
- GSK
- Inspire
- Inverseon
- Johnson & Johnson
- Kyorin
- MAP Pharmaceuticals
- Meda
- MediciNova
- MedImmune
- Menarini
- Merck
- Merck KGaA
- Mitsubishi Tanabe Pharma
- NicOx
- Nippon Shinyaku
- Novartis
- Nycomed Pharma
- Orexo
- Pfizer
- Pierre Fabre
- Purdue/Mundipharma
- Rigel
- Roche
- Rottapharm
- Sanofi-Aventis
- Schering Plough
- Scripps Research Institute
- Sepracor
- Shionogi
- Sosei
- Theravance
- Topigen
- Vectura
- Wyeth
- Yuhan
|
